




The Open PHACTS Discovery Platform

Semantic Data Integration for Life Sciences







Resulting in a sales revenu

Generic Competition

Value of patent expiries 2001-2015 (constant



PwC - Pharma 2020 Improve
R&D
Productivity





Figure 1: The decline in R&D productivity



NME:

New chemical or biological prescription therapeutic: excludes vaccines, antigens and combination therapies which do not include at least one new constituents


Source: FDA CDER, PhRMA and PricewaterhouseCoopers analysis
Note: Data on R&D spending for non-PhRMA companies are not included here.





Pre-competitive Informatics:

Pharma are all accessing, processing, storing & re-processing external research data



Lowering industry firewalls: pre-competitive informatics in drug discovery Nature Reviews Drug Discovery (2009) 8, 701-708 doi:10.1038/nrd2944





Over the last decade

- Data has become more open
- Data has become better represented (Standards)
- Major providers are becoming more organised (NCBI, EBI, FDA)

BUT

Integration across sources, and across providers is still a gap















The Innovative Medicines Initiative

- EC funded publicprivate partnership for pharmaceutical research
- Focus on key problems
 - Efficacy, Safety,
 Education &
 Training,
 Knowledge
 Management



The Open PHACTS Project

- Create a semantic integration hub ("Open Pharmacological Space")...
- Runs 2011-2014, ENSO till 2016
- Deliver services to support on-going drug discovery programs in pharma and public domain
- Leading academics in semantics, pharmacology and informatics, driven by solid industry business requirements
- 31 academic partners, 9 pharmaceutical companies, 3 software SMEs
- Work split into clusters:
 - Technical Build
 - Scientific Drive
 - Community & Sustainability





Open PHACTS Mission:
Integrate Multiple Research
Biomedical Data Resources
Into A Single Open & Free
Access Point






"What is the selectivity profile of known p38 inhibitors?"




"Let me compare MW, logP and PSA for known oxidoreductase inhibitors"





ChEMBL



Gene Ontology

Wikipathways

GeneGo

ChEBI

UniProt

UMLS

GVKBio

ConceptWiki

ChemSpider

TrialTrove

TR Integrity





Business Question Driven Approach

Number	sum	Nr of 1	Question			
15	12	9	All oxidoreductase inhibitors active <100nM in both human and mouse			
18	14	8	Given compound X, what is its predicted secondary pharmacology? What are the on and off,target safety concerns for a compound? What is the evidence and how reliable is that evidence (journal impact factor, KOL) for findings associated with a compound?			
24	13	8		get find me all a ADMET profile o	actives against that target. Find/predict polypharmacology of actives. of actives.	
32	13	8	For a given	-acceptedededelcars		
37	13	8	The curren in serine pr		Volume 18, Issues 17–18, September 2013, Pages 843–852	
38	13	8	Retrieve all structure (v	ELSEVIER		
41	13	8	A project is compounds the target of level of the	Review Scientific competency questions as the basis for semantically		
44	13	8	Give me al	enriched open pharmacological space development		
46	13	8	Give me th (disease)	rtanta / Ezada , Eagar vados , Storar vongor , Emmano vadarado rtodrigade , Masor zoza , Barst		
59	14	8	Identify all	Taboureau ⁸ , Matthias Rarey ⁹ , Christine Chichester ¹⁰ , Steve Pettifer ¹¹ , Niklas Blomberg ^{12, a} , Lee		



Drug Discovery Today



Scientific competency questions as the basis for semantically enriched open pharmacological space development

Kamal Azzaoui¹, Edgar Jacoby¹⁴, Stefan Senger², Emiliano Cuadrado Rodríguez³, Mabel Loza³, Barbara Zdrazil⁴, Marta Pinto⁴, Antony J. Williams⁵, Victor de la Torre⁶, Jordi Mestres⁷, Manuel Pastor⁷, Olivier Taboureau⁸, Matthias Rarey⁹, Christine Chichester¹⁰, Steve Pettifer¹¹, Niklas Blomberg^{12, a}, Lee Harland¹³, Bryn Williams-Jones¹³, Gerhard F. Ecker⁴, ♣ , ■





The Open PHACTS Discovery Platform

- Cloud-Based "Production" Level System. Secure & Private
- Guided By Business Questions
- Uses Semantic Web
 Technology <u>But</u> provides
 a simple REST-ful API for
 everyone else



Drug Discovery Today

Volume 18, Issues 17-18, September 2013, Pages 843-852



Review

Scientific competency questions as the basis for semantically enriched open pharmacological space development

Kamal Azzaoui¹, Edgar Jacoby¹⁴, Stefan Senger², Emiliano Cuadrado Rodríguez³, Mabel Loza³, Barbara Zdrazil⁴, Marta Pinto⁴, Antony J. Williams⁵, Victor de la Torre⁶, Jordi Mestres⁷, Manuel Pastor⁷, Olivier Taboureau⁸, Matthias Rarey⁹, Christine Chichester¹⁰, Steve Pettifer¹¹, Niklas Blomberg^{12, a}, Lee Harland¹³, Bryn Williams-Jones¹³, Gerhard F. Ecker^{4.} ♣ .

■

http://dx.doi.org/10.1016/j.drudis.2013.05.008



Web Semantics: Science, Services and Agents on the World Wide Web





In Press, Accepted Manuscript - Note to users

API-centric Linked data integration: The open PHACTS discovery platform case study

Paul Groth^a. ▲ № Antonis Loizou^a, Alasdair J.G. Gray^d, Carole Goble^b, Lee Harland^c, Steve Pettifer^b http://dx.doi.org/10.1016/j.websem.2014.03.003





HOW STANDARDS PROLIFERATE: (SEE: A/C CHARGERS, CHARACTER ENCODINGS, INSTANT MESSAGING, ETC.)

SITUATION: THERE ARE 14 COMPETING STANDARDS.





SITUATION: THERE ARE 15 COMPETING STANDARDS.

http://imgs.xkcd.com/comics/standards.png

- Basic Semantic web standards
 - SPARQL 1.1, RDF(S), SKOS
- Dataset descriptions
 - Vocabulary of Interlinked Datasets (VoID)
 - VoID linkset descriptions


- QUDT Quantities, Units, Dimensions and Types
- Provenance
 - W3C PROV, PAV, Nanopublications
- BioPortal, ConceptWiki, ChEMBL, identifiers.org, Uniprot, ChemSpider





HELLO my name is


P12047 X31045








Are These Two Molecules The Same(*)










*Really: Is it sensible to combine data associated with these two molecules?













Sign in | Sign up

Developer Home

Want help?

Documentation

Get my API keys

Featured Apps

Workflo

Create!

Build with the Open PHACTS Discovery Platform. The platform provides a convenient API to query across multiple pharmacology datasets.

You'll find complete documentation for the API in our <u>documentation</u> section. You'll need an API key to use the platform. <u>Sign-up</u> is free. For more information on the project, check out www.openphacts.org.

News:

- . Let us know if you have a feature request or bug report.
- August 11, 2014 version 1.4 of the platform is made available.
- June 24, 2014 Open PHACTS Foundation announces first 3 members.
- January 24, 2014 version 1.3 of the platform is made available.
- April 22, 2013 launch of public beta at the 4th Open PHACTS community workshop held at the Royal Society of Chemistry. Great turnout!

Powered By:




















© 2015

Powered by @3scale















http://www.openphactsfoundation.org/apps.html




































Sustaining Impact

"Software is free like puppies are free they both need money for maintenance"



...and more resource for future development







Open PHACTS Mission:
Integrate Multiple Research
Biomedical Data Resources
Into A Single Open & Free
Access Point













Advancing the Chemical Sciences

Maastricht University





code^N

Open PHACTS Associate

AstraZeneca Partner Community







Ian Harrow Consulting

Oontoforce



Genetta

inte:ligand

MGH

LDBC 🚯




































orphanet















































OPF is a not-for-profit membership organisation, supporting the Open PHACTS Discovery Platform:

A sustainable, open, vibrant and interoperable information infrastructure for applied life science research and development.

To reduce the barriers to drug discovery in industry, academia and for small businesses, the Open PHACTS Discovery Platform provides tools and services to interact with multiple integrated and publicly available data sources. To integrate this data, extensive cross-referencing of scientific concepts is needed across all databases.

The Open PHACTS Foundation ensures the sustainability of the Open PHACTS Discovery Platform infrastructure and acts as a hub for relevant scientific research and development.



















Key Resources

▲ Open PHACTS API

5 Open PHACTS Repository

Subscribe to the Foundation Newsletter

email address

Subscribe

Contact us

info@openphactsfoundation.org

> Twitter: @Open PHACTS

Membership Benefits



The not-for-profit Foundation maintains the Open PHACTS Discovery Platform, a versatile infrastructure of integrated biomedical data, and actively engages an ecosystem of industry and academic semantic web experts.

Integrated data:

Pharmacological

Physicochemical

Disease

Gene

Pathways

Steer the direction

- Prioritise new projects
- Get involved with Foundation governance
- Identify development opportunities
- Propose new data sources to include
- Develop new use-cases and workflows

Training opportunities

Enjoy training opportunities by experts.

Early access to releases

Members have early access to infrastructure and platform updates and new releases, including a locally installable system

Engage a community of experts and peers

The Foundation serves a unique and vibrant scientific community, facilitating collaboration between the pharma industry, academia & SMEs.

Influence the security policy

Membership Levels

Full Nominate and vote for the Board of Trustees

turnover. Pay in cash or by donating people-hours to the Foundation.

Contributing

Vote for the Board of Trustees

Individual

Non-voting

Get involved in projects and collaborate

www.openphactsfoundation.org

info@openphactsfoundation.org

Open PHACTS Foundation

c/o Royal Society of Chemistry, Thomas Graham House, Science Park, Cambridge, CB4 0WF

bryn@openphactsfoundation.org

Acknowledgements









































































Technical University of Denmark
University of Hamburg, Center for
Bioinformatics

BioSolveIT GmBH

Consorci Mar Parc de Salut de Barcelona

Leiden University Medical Centre

Royal Society of Chemistry

Vrije Universiteit Amsterdam

Novartis

Merck Serono

H. Lundbeck A/S

Eli Lilly

Netherlands Bioinformatics Centre Swiss Institute of Bioinformatics

ConnectedDiscovery

EMBL-European Bioinformatics Institute

Janssen Esteve Almirall

OpenLink Scibite

The Open PHACTS Foundation

Spanish National Cancer Research Centre

University of Manchester

Maastricht University

Aqnowledge

University of Santiago de Compostela

Rheinische Friedrich-Wilhelms-Universität Bonn

AstraZeneca

Pfizer